Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis
Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.